Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Margetuximab-cmkb + Paclitaxel + Pertuzumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Margetuximab-cmkb||Margenza||MGAH22|MGAH-22||HER2 (ERBB2) Antibody 60||Margenza (margetuximab-cmkb) is a monoclonal antibody that binds ERBB2 (HER2) and induces antitumor response against ERBB2 (HER2)-expressing tumor cells (PMID: 22129105, PMID: 32653053). Margenza (margetuximab-cmkb) in combination with chemotherapy is FDA approved for use in patients with metastatic ERBB2 (HER2)-positive breast cancer who had received two or more prior anti-ERBB2 (HER2) therapies (FDA.gov).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 14 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Pertuzumab||Perjeta||2C4 Antibody||HER2 (ERBB2) Antibody 60||Perjeta (pertuzumab) is a monoclonal antibody that binds ERBB2 (HER2) to prevent dimerization and subsequent HER signaling, thereby resulting in apoptosis and tumor growth inhibition (PMID: 15699478). Perjeta (pertuzumab) is FDA approved in combination with Herceptin (trastuzumab) and Taxotere (docetaxel) for patients with ERBB2 (HER2)-positive breast cancer and in combination with Herceptin (trastuzumab) and chemotherapy as neoadjuvant treatment for patients with ERBB2 (HER2)-positive breast cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04425018||Phase II||Paclitaxel + Pertuzumab + Trastuzumab Margetuximab-cmkb + Paclitaxel + Pertuzumab||MARGetuximab Or Trastuzumab (MARGOT)||Recruiting||USA||0|